Lilly Steps Into Psychedelic Mental Health Market

Eli Lilly, a big drug company, will buy AtaiBeckley. This deal is worth $2.8 billion at first. It shows Lilly's interest in new ways to treat mental health issues.

This move puts Lilly in a new area. Other companies, like Johnson & Johnson, also look at these treatments. Psychedelic medicines may help people with mental health problems.

Lilly's decision could change how we think about mental health care. It brings more money and research to this growing field. This could lead to new treatments for many people seeking help.

Source: FierceBiotech